Pharma giant Novartis is spinning off its eye-care business (NVS)

Novartis CEO Vas NarasimhanReuters

Swiss pharma giant Novartis is planning to spin off its Alcon eye-care business. 
The company also plans to buy back up to $5 billion in stock as it refocuses on prescription drugs. 
Once it is spun off from Novartis and distributed among investors Alcon, which has $7 billion in annual sales, will have its main listing and headquarters in Switzerland.

ZURICH (Reuters) – Novartis plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs.

Alcon, a legacy from former Novartis boss Daniel Vasella’s empire building, has been problematic since it was bought for $52 billion in 2011. Narasimhan declined to give a valuation for the business on Friday, although his predecessor Joe Jimenez once estimated it at only $25-$35 billion.See the rest of the story at Business Insider

NOW WATCH: Trump pitched peace to Kim Jong Un with this Hollywood-style video starring Kim as the leading man

See Also:

China assures EU of good intent at Eastern Europe summitsThai PM visits cave where boys’ soccer team feared trappedChina’s Xiaomi prices Hong Kong IPO at bottom of range: IFR

SEE ALSO: Amazon’s playbook for upending healthcare just got a lot clearer — here’s why it should terrify the pharmaceutical industry

Read more:

Do NOT follow this link or you will be banned from the site!

Copyright - CelebTrends.Net - Privacy Policy - Terms of Use - Disclaimer - AMAZON Affiliate Disclosure